Logo Made in Germany BIO 2017

Medigene AG

Booth number: 4507-6

About us

Short Profile

  • Focus on T-cell-directed immunotherapies
  • Proprietary programs in indications with high medical need, beginning with hematological malignancies, followed by solid tumor indications
  • Dendritic cell vaccines (DCs) in ongoing clinical phase I/II trial
  • T-cell receptor-modified T cells (TCRs): lead candidates close to clinical development
  • Over 90 employees with expertise in immunotherapy and pharmaceutical development
  • Headquartered in Martinsried near Munich (Germany), with US-offices in Washington, D.C. and San Diego, California
  • Listed on Frankfurt Stock Exchange: MDG1; TecDAX; ISIN DE000A1X3W00

Products and services

Medigene has applied its extensive know-how relating to T cells and their control to establish three innovative platform technologies centered on the T cell as the most potent player in the immune system to combat cancer.

Our three complementary platforms are designed to treat multiple types of cancer and different stages of disease, so that optimally tailored T-cell responses can be provided to individual patients according to their medical needs:

T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy provide potential treatments for patients with large tumor burdens.

Dendritic cell (DC) vaccines are intended for the treatment of low tumor burdens such as minimal residual disease or for use in combination therapies.

T-cell-specific monoclonal antibodies (TABS) identify T cells based on their unique T-cell receptors.

Medigene's immunotherpies

Medigene's immunotherpies

Medigene focuses on the development of living immunotherapies to treat different forms of cancer. Living immunotherapies are treatments based on living cells made from a patient’s own immune cells.

News & Innovations

The Medigene Investment Case 
  • Medigene’s immunotherapy programs are deeply rooted in world-class science
  • Established company for biopharmaceutical product development from research to market approval
  • Management team composed of Medigene’s immunotherapies inventors in addition to very experienced executives from the biopharmaceutical industry
  • Up-scalable technology platforms for fueling continual development of candidates for the pipeline – for Medigene and Partners
  • Unique knowledge and speed on TCR discovery and validation
  • Well funded


Medigene AG
Lochhamer Str. 11
82152 Martinsried

Phone: +49 89 2000330
Fax: +49 89 2000332920

Dr. Robert Mayer
Senior Manager Public & Investor Relations
Phone: +49 89 2000330

Business matching
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.

Click here if you notice an image that violates copyright or privacy rights.

Your personal organizer

Your personal organizer

Print list  |  Save as PDF
Xell AG
Booth number: